Apixaban is safer than rivaroxaban in AF: study
Choosing between the two drugs is a choice between thrombotic or haemorrhagic risk
Apixaban is associated with a lower risk of major bleeding and thrombotic events compared with rivaroxaban, a large real-world data analysis shows.
US and Canadian researchers, who assessed outcomes of 90,000 elderly patients with non-valvular AF who were newly prescribed one of the novel oral anticoagulants (NOACs), said their results confirmed apixaban as the safer option.
